 | • レポートコード：MRC2-11QY13555 • 出版社/出版日：QYResearch / 2020年11月30日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は後天性孤児造血疾患治療薬のグローバル市場について調査・分析したレポートです。種類別（投薬、骨髄移植、輸血、鉄療法）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別後天性孤児造血疾患治療薬の競争状況、市場シェア ・世界の後天性孤児造血疾患治療薬市場：種類別市場規模 2015年-2020年（投薬、骨髄移植、輸血、鉄療法） ・世界の後天性孤児造血疾患治療薬市場：種類別市場規模予測 2021年-2026年（投薬、骨髄移植、輸血、鉄療法） ・世界の後天性孤児造血疾患治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の後天性孤児造血疾患治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の後天性孤児造血疾患治療薬市場分析：米国、カナダ ・ヨーロッパの後天性孤児造血疾患治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの後天性孤児造血疾患治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の後天性孤児造血疾患治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの後天性孤児造血疾患治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Alexion Pharmaceuticals、Amgen、Celgene Corporation、Eli Lilly、Sanofi、GlaxoSmithKline、Cyclacel Pharmaceuticals、Onconova Therapeutics、Incyte Corporation、CTI BioPharma ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Acquired orphan blood disease is a type of rare blood disorder, which occurs due to the presence of insufficient amount of red blood cells in the blood. This disease is characterized by the body’s inability to produce red blood cells. Moreover, improper functioning of bone marrow also leads to lack of red blood cells in blood, which in turn results in a decrease in platelet numbers. This decrease in platelet number causes anemia and thrombosis.
Soliris (eculizumab) is a perfect example of a successful orphan blood disease drug. PNH is a potentially life-threatening blood disease, characterised by severe anemia caused by the destruction of red blood cells in the bloodstream. Bone marrow transplants can provide a cure, but the high risk procedure is suitable for only a few patients. Treatment methods include blood transfusions, iron therapy, and growth factors, but monoclonal antibody
Market Analysis and Insights: Global Acquired Orphan Blood Diseases Therapeutics Market
The global Acquired Orphan Blood Diseases Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Acquired Orphan Blood Diseases Therapeutics Scope and Market Size
Acquired Orphan Blood Diseases Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Acquired Orphan Blood Diseases Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Alexion Pharmaceuticals
Amgen
Celgene Corporation
Eli Lilly
Sanofi
GlaxoSmithKline
Cyclacel Pharmaceuticals
Onconova Therapeutics
Incyte Corporation
CTI BioPharma
Market segment by Type, the product can be split into
Medication
Bone Marrow Transplant
Blood Transfusion
Iron Therapy
Market segment by Application, split into
Hospitals
Clinics
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Acquired Orphan Blood Diseases Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Acquired Orphan Blood Diseases Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Medication
1.4.3 Bone Marrow Transplant
1.4.4 Blood Transfusion
1.4.5 Iron Therapy
1.5 Market by Application
1.5.1 Global Acquired Orphan Blood Diseases Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Acquired Orphan Blood Diseases Therapeutics Market Perspective (2015-2026)
2.2 Global Acquired Orphan Blood Diseases Therapeutics Growth Trends by Regions
2.2.1 Acquired Orphan Blood Diseases Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Acquired Orphan Blood Diseases Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Acquired Orphan Blood Diseases Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Acquired Orphan Blood Diseases Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Acquired Orphan Blood Diseases Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Acquired Orphan Blood Diseases Therapeutics Players by Market Size
3.1.1 Global Top Acquired Orphan Blood Diseases Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Acquired Orphan Blood Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Acquired Orphan Blood Diseases Therapeutics Market Concentration Ratio
3.2.1 Global Acquired Orphan Blood Diseases Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Acquired Orphan Blood Diseases Therapeutics Revenue in 2019
3.3 Acquired Orphan Blood Diseases Therapeutics Key Players Head office and Area Served
3.4 Key Players Acquired Orphan Blood Diseases Therapeutics Product Solution and Service
3.5 Date of Enter into Acquired Orphan Blood Diseases Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Acquired Orphan Blood Diseases Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Acquired Orphan Blood Diseases Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020)
5.2 Global Acquired Orphan Blood Diseases Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Acquired Orphan Blood Diseases Therapeutics Market Size (2015-2020)
6.2 Acquired Orphan Blood Diseases Therapeutics Key Players in North America (2019-2020)
6.3 North America Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020)
6.4 North America Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Acquired Orphan Blood Diseases Therapeutics Market Size (2015-2020)
7.2 Acquired Orphan Blood Diseases Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020)
7.4 Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Acquired Orphan Blood Diseases Therapeutics Market Size (2015-2020)
8.2 Acquired Orphan Blood Diseases Therapeutics Key Players in China (2019-2020)
8.3 China Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020)
8.4 China Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Acquired Orphan Blood Diseases Therapeutics Market Size (2015-2020)
9.2 Acquired Orphan Blood Diseases Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020)
9.4 Japan Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Acquired Orphan Blood Diseases Therapeutics Market Size (2015-2020)
10.2 Acquired Orphan Blood Diseases Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Acquired Orphan Blood Diseases Therapeutics Market Size (2015-2020)
11.2 Acquired Orphan Blood Diseases Therapeutics Key Players in India (2019-2020)
11.3 India Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020)
11.4 India Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Acquired Orphan Blood Diseases Therapeutics Market Size (2015-2020)
12.2 Acquired Orphan Blood Diseases Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Alexion Pharmaceuticals
13.1.1 Alexion Pharmaceuticals Company Details
13.1.2 Alexion Pharmaceuticals Business Overview
13.1.3 Alexion Pharmaceuticals Acquired Orphan Blood Diseases Therapeutics Introduction
13.1.4 Alexion Pharmaceuticals Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020))
13.1.5 Alexion Pharmaceuticals Recent Development
13.2 Amgen
13.2.1 Amgen Company Details
13.2.2 Amgen Business Overview
13.2.3 Amgen Acquired Orphan Blood Diseases Therapeutics Introduction
13.2.4 Amgen Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020)
13.2.5 Amgen Recent Development
13.3 Celgene Corporation
13.3.1 Celgene Corporation Company Details
13.3.2 Celgene Corporation Business Overview
13.3.3 Celgene Corporation Acquired Orphan Blood Diseases Therapeutics Introduction
13.3.4 Celgene Corporation Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020)
13.3.5 Celgene Corporation Recent Development
13.4 Eli Lilly
13.4.1 Eli Lilly Company Details
13.4.2 Eli Lilly Business Overview
13.4.3 Eli Lilly Acquired Orphan Blood Diseases Therapeutics Introduction
13.4.4 Eli Lilly Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020)
13.4.5 Eli Lilly Recent Development
13.5 Sanofi
13.5.1 Sanofi Company Details
13.5.2 Sanofi Business Overview
13.5.3 Sanofi Acquired Orphan Blood Diseases Therapeutics Introduction
13.5.4 Sanofi Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020)
13.5.5 Sanofi Recent Development
13.6 GlaxoSmithKline
13.6.1 GlaxoSmithKline Company Details
13.6.2 GlaxoSmithKline Business Overview
13.6.3 GlaxoSmithKline Acquired Orphan Blood Diseases Therapeutics Introduction
13.6.4 GlaxoSmithKline Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020)
13.6.5 GlaxoSmithKline Recent Development
13.7 Cyclacel Pharmaceuticals
13.7.1 Cyclacel Pharmaceuticals Company Details
13.7.2 Cyclacel Pharmaceuticals Business Overview
13.7.3 Cyclacel Pharmaceuticals Acquired Orphan Blood Diseases Therapeutics Introduction
13.7.4 Cyclacel Pharmaceuticals Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020)
13.7.5 Cyclacel Pharmaceuticals Recent Development
13.8 Onconova Therapeutics
13.8.1 Onconova Therapeutics Company Details
13.8.2 Onconova Therapeutics Business Overview
13.8.3 Onconova Therapeutics Acquired Orphan Blood Diseases Therapeutics Introduction
13.8.4 Onconova Therapeutics Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020)
13.8.5 Onconova Therapeutics Recent Development
13.9 Incyte Corporation
13.9.1 Incyte Corporation Company Details
13.9.2 Incyte Corporation Business Overview
13.9.3 Incyte Corporation Acquired Orphan Blood Diseases Therapeutics Introduction
13.9.4 Incyte Corporation Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020)
13.9.5 Incyte Corporation Recent Development
13.10 CTI BioPharma
13.10.1 CTI BioPharma Company Details
13.10.2 CTI BioPharma Business Overview
13.10.3 CTI BioPharma Acquired Orphan Blood Diseases Therapeutics Introduction
13.10.4 CTI BioPharma Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020)
13.10.5 CTI BioPharma Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Acquired Orphan Blood Diseases Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Acquired Orphan Blood Diseases Therapeutics Revenue
Table 3. Ranking of Global Top Acquired Orphan Blood Diseases Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Acquired Orphan Blood Diseases Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Medication
Table 6. Key Players of Bone Marrow Transplant
Table 7. Key Players of Blood Transfusion
Table 8. Key Players of Iron Therapy
Table 9. Global Acquired Orphan Blood Diseases Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Acquired Orphan Blood Diseases Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Acquired Orphan Blood Diseases Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Regions (2015-2020)
Table 13. Global Acquired Orphan Blood Diseases Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Acquired Orphan Blood Diseases Therapeutics Market Growth Strategy
Table 19. Main Points Interviewed from Key Acquired Orphan Blood Diseases Therapeutics Players
Table 20. Global Acquired Orphan Blood Diseases Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 21. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Players (2015-2020)
Table 22. Global Top Acquired Orphan Blood Diseases Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Acquired Orphan Blood Diseases Therapeutics as of 2019)
Table 23. Global Acquired Orphan Blood Diseases Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Acquired Orphan Blood Diseases Therapeutics Product Solution and Service
Table 26. Date of Enter into Acquired Orphan Blood Diseases Therapeutics Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 29. Global Acquired Orphan Blood Diseases Therapeutics Market Size Share by Type (2015-2020)
Table 30. Global Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Type (2021-2026)
Table 31. Global Acquired Orphan Blood Diseases Therapeutics Market Size Share by Application (2015-2020)
Table 32. Global Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 33. Global Acquired Orphan Blood Diseases Therapeutics Market Size Share by Application (2021-2026)
Table 34. North America Key Players Acquired Orphan Blood Diseases Therapeutics Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Acquired Orphan Blood Diseases Therapeutics Market Share (2019-2020)
Table 36. North America Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 37. North America Acquired Orphan Blood Diseases Therapeutics Market Share by Type (2015-2020)
Table 38. North America Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 39. North America Acquired Orphan Blood Diseases Therapeutics Market Share by Application (2015-2020)
Table 40. Europe Key Players Acquired Orphan Blood Diseases Therapeutics Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Acquired Orphan Blood Diseases Therapeutics Market Share (2019-2020)
Table 42. Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Acquired Orphan Blood Diseases Therapeutics Market Share by Type (2015-2020)
Table 44. Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Acquired Orphan Blood Diseases Therapeutics Market Share by Application (2015-2020)
Table 46. China Key Players Acquired Orphan Blood Diseases Therapeutics Revenue (2019-2020) (Million US$)
Table 47. China Key Players Acquired Orphan Blood Diseases Therapeutics Market Share (2019-2020)
Table 48. China Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 49. China Acquired Orphan Blood Diseases Therapeutics Market Share by Type (2015-2020)
Table 50. China Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 51. China Acquired Orphan Blood Diseases Therapeutics Market Share by Application (2015-2020)
Table 52. Japan Key Players Acquired Orphan Blood Diseases Therapeutics Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Acquired Orphan Blood Diseases Therapeutics Market Share (2019-2020)
Table 54. Japan Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Acquired Orphan Blood Diseases Therapeutics Market Share by Type (2015-2020)
Table 56. Japan Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Acquired Orphan Blood Diseases Therapeutics Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Acquired Orphan Blood Diseases Therapeutics Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Acquired Orphan Blood Diseases Therapeutics Market Share (2019-2020)
Table 60. Southeast Asia Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Acquired Orphan Blood Diseases Therapeutics Market Share by Type (2015-2020)
Table 62. Southeast Asia Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Acquired Orphan Blood Diseases Therapeutics Market Share by Application (2015-2020)
Table 64. India Key Players Acquired Orphan Blood Diseases Therapeutics Revenue (2019-2020) (Million US$)
Table 65. India Key Players Acquired Orphan Blood Diseases Therapeutics Market Share (2019-2020)
Table 66. India Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 67. India Acquired Orphan Blood Diseases Therapeutics Market Share by Type (2015-2020)
Table 68. India Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 69. India Acquired Orphan Blood Diseases Therapeutics Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Acquired Orphan Blood Diseases Therapeutics Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Acquired Orphan Blood Diseases Therapeutics Market Share (2019-2020)
Table 72. Central & South America Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Acquired Orphan Blood Diseases Therapeutics Market Share by Type (2015-2020)
Table 74. Central & South America Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Acquired Orphan Blood Diseases Therapeutics Market Share by Application (2015-2020)
Table 76. Alexion Pharmaceuticals Company Details
Table 77. Alexion Pharmaceuticals Business Overview
Table 78. Alexion Pharmaceuticals Product
Table 79. Alexion Pharmaceuticals Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) (Million US$)
Table 80. Alexion Pharmaceuticals Recent Development
Table 81. Amgen Company Details
Table 82. Amgen Business Overview
Table 83. Amgen Product
Table 84. Amgen Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) (Million US$)
Table 85. Amgen Recent Development
Table 86. Celgene Corporation Company Details
Table 87. Celgene Corporation Business Overview
Table 88. Celgene Corporation Product
Table 89. Celgene Corporation Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) (Million US$)
Table 90. Celgene Corporation Recent Development
Table 91. Eli Lilly Company Details
Table 92. Eli Lilly Business Overview
Table 93. Eli Lilly Product
Table 94. Eli Lilly Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) (Million US$)
Table 95. Eli Lilly Recent Development
Table 96. Sanofi Company Details
Table 97. Sanofi Business Overview
Table 98. Sanofi Product
Table 99. Sanofi Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) (Million US$)
Table 100. Sanofi Recent Development
Table 101. GlaxoSmithKline Company Details
Table 102. GlaxoSmithKline Business Overview
Table 103. GlaxoSmithKline Product
Table 104. GlaxoSmithKline Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) (Million US$)
Table 105. GlaxoSmithKline Recent Development
Table 106. Cyclacel Pharmaceuticals Company Details
Table 107. Cyclacel Pharmaceuticals Business Overview
Table 108. Cyclacel Pharmaceuticals Product
Table 109. Cyclacel Pharmaceuticals Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) (Million US$)
Table 110. Cyclacel Pharmaceuticals Recent Development
Table 111. Onconova Therapeutics Business Overview
Table 112. Onconova Therapeutics Product
Table 113. Onconova Therapeutics Company Details
Table 114. Onconova Therapeutics Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) (Million US$)
Table 115. Onconova Therapeutics Recent Development
Table 116. Incyte Corporation Company Details
Table 117. Incyte Corporation Business Overview
Table 118. Incyte Corporation Product
Table 119. Incyte Corporation Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) (Million US$)
Table 120. Incyte Corporation Recent Development
Table 121. CTI BioPharma Company Details
Table 122. CTI BioPharma Business Overview
Table 123. CTI BioPharma Product
Table 124. CTI BioPharma Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) (Million US$)
Table 125. CTI BioPharma Recent Development
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Medication Features
Figure 3. Bone Marrow Transplant Features
Figure 4. Blood Transfusion Features
Figure 5. Iron Therapy Features
Figure 6. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Application: 2020 VS 2026
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Others Case Studies
Figure 10. Acquired Orphan Blood Diseases Therapeutics Report Years Considered
Figure 11. Global Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Regions: 2020 VS 2026
Figure 13. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Players in 2019
Figure 16. Global Top Acquired Orphan Blood Diseases Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Acquired Orphan Blood Diseases Therapeutics as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Acquired Orphan Blood Diseases Therapeutics Revenue in 2019
Figure 18. North America Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed
後天性孤児血液疾患の世界市場（～2026年） Acquired orphan blood disease is a type of rare blood disorder, which occurs due to the presence of insufficient amount of red blood cells in the blood. This disease is characterized by the body?s inability to produce red blood cells. Moreover, improper functioning of bone marrow also leads to lack …- 希少疾患の世界市場（～2026年） An orphan disease is defined as a condition that affects fewer than 200,000 people nationwide. This includes diseases as familiar as cystic fibrosis, Lou Gehrig's disease, and Tourette's syndrome, and as unfamiliar as Hamburger disease, Job syndrome, and acromegaly, or "gigantism." Some diseases hav…
- 希少性肺疾患治療の世界市場（～2026年） Orphan illnesses are those which are not generally looked into, those where particular medicines are not accessible, and those which may just be of restricted enthusiasm to researchers and specialists. Orphan lung diseases are exemplified by the purported disregarded infectious diseases, which are e…
- 市中肺炎（CAP）の世界市場（～2026年） Community-acquired pneumonia (CAP) refers to pneumonia (any of several lung diseases) contracted by a person with little contact with the healthcare system. The market of CAP treatment and diagnosis in further segmented with respect to major geographies of North America, Europe, Asia-Pacific, and La…
- 幹細胞臍帯血の世界市場（～2026年） Umbilical cord blood (UCB) stem cells have gained much significance in medical science owing to their ability to transform into any type of human cells. UCB refers to the blood that remains in the attached umbilical cord and placenta after childbirth. Stem cells that UCB contains are considered uniq…